Screening for TP53 mutations in Swedish breast cancer families
Author Information
Author(s): M Zelada-Hedman, A-L B0rresen-Dale, A Clarol, J Chen, L Skoog, A Lindblom
Primary Institution: Karolinska Hospital, Stockholm, Sweden; Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway
Hypothesis
What is the prevalence of TP53 mutations in familial breast cancer?
Conclusion
No germline mutations were found in the patients, but mutations were detected in 14% of the tumor DNA samples.
Supporting Evidence
- No germline mutations were found in any of the patients.
- Mutations were found in 14% of the tumor DNA samples.
- The frequency of somatic mutations in familial tumors is similar to sporadic breast tumors.
- Previous studies suggested that TP53 mutations are involved in approximately 1% of familial breast cancer cases.
Takeaway
The study looked for changes in a gene called TP53 in families with breast cancer and found that while the gene didn't have changes in the patients, some tumors did have changes.
Methodology
Constant denaturant gel electrophoresis (CDGE) was used to screen exons 5-8 of the TP53 gene for germline mutations in 128 patients from 109 families.
Limitations
The study confirms the low frequency of germline mutations in p53, suggesting limited clinical benefit in screening for these mutations in breast cancer families.
Participant Demographics
Patients were from 109 families with a history of familial breast cancer.
Want to read the original?
Access the complete publication on the publisher's website